Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Free Cash Flow (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Free Cash Flow for 10 consecutive years, with -$34.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 26.42% to -$34.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$190.0 million through Dec 2025, up 9.48% year-over-year, with the annual reading at -$190.0 million for FY2025, 9.48% up from the prior year.
  • Free Cash Flow hit -$34.5 million in Q4 2025 for Rocket Pharmaceuticals, up from -$50.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$18.6 million in Q4 2023 to a low of -$61.8 million in Q3 2023.
  • Historically, Free Cash Flow has averaged -$45.2 million across 5 years, with a median of -$47.6 million in 2024.
  • Biggest five-year swings in Free Cash Flow: surged 64.7% in 2023 and later tumbled 151.58% in 2024.
  • Year by year, Free Cash Flow stood at -$32.9 million in 2021, then tumbled by 60.34% to -$52.8 million in 2022, then soared by 64.7% to -$18.6 million in 2023, then crashed by 151.58% to -$46.9 million in 2024, then grew by 26.42% to -$34.5 million in 2025.
  • Business Quant data shows Free Cash Flow for RCKT at -$34.5 million in Q4 2025, -$50.4 million in Q3 2025, and -$49.0 million in Q2 2025.